Lenalidomid HEXAL 25 mg Hartkapseln clinical trials

A randomized phase III non-inferiority trial assessing lenalidomide, bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in transplant-eligible patients with newly diagnosed multiple myeloma (GMMG HD8/ DSMM XIX)

This study looks at new ways to treat multiple myeloma, a type of blood cancer. It compares giving a new medicine called isatuximab in two different ways (through a drip or an injection) alongside standard treatments. The aim is to see if an injection works as well as a drip.